News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY), Evotec AG (EVTG.F) Sign Alzheimer's Pact Worth Up to $830 Million


9/6/2011 7:59:57 AM

Roche Holding AG (ROG) will pay Evotec AG (EVT) $10 million for the right to develop Evotec’s EVT 302 compound for Alzheimer’s disease. Evotec may receive as much as another $820 million if development and sales goals are met, as well as double-digit royalties, the Hamburg-based company said in a statement today. Basel, Switzerland-based Roche will pay for clinical development, manufacturing and commercialization, Evotec said. The compound targets monoamine oxidase type B, or MAO-B, an enzyme that breaks down dopamine in the brain and contributes to the production of free radicals, which may contribute to the spread of the disease, Evotec said.


comments powered by Disqus
Evotec AG
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES